Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.
about
Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populationsTime trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: Data from the SWEDEHEART registry.Leukocyte Trafficking in Cardiovascular Disease: Insights from Experimental ModelsPersonalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors.Long term health outcomes in patients with a history of myocardial infarction: A population based cohort studyInitiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.Long-term secondary prevention of acute myocardial infarction (SEPAT) - guidelines adherence and outcome.Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic reviewGender differences in all-cause, cardiovascular and cancer mortality during long-term follow-up after acute myocardial infarction; a prospective cohort study.Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.Atherosclerosis: Successes, Surprises, and Future Challenges.Innate immune cells in ischaemic heart disease: does myocardial infarction beget myocardial infarction?Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study.Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study."One-Time" versus Staged Multivessel Intervention in Intermediate to Very High-Risk Patients with Non-ST-Segment Elevation Acute Coronary Syndromes.Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland.Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.Antiplatelet therapy in acute coronary syndromes.Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.The year in cardiology 2015: acute coronary syndromes.Medical Therapy and Recurrent Ischemic Events in High Risk Patients Surviving their Myocardial Infarction for at Least 12 Months: Comparison of Patients with ST Elevation Versus Non-ST Elevation Myocardial Infarction.Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.Which long-term antiplatelet regimen for patients with acute coronary syndromes?Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction.Dual antiplatelet therapy after coronary stenting.Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program.Phase 2 Randomised Controlled Trial and Feasibility Study of Future Care Planning in Patients with Advanced Heart Disease.Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study.Duration of dual antiplatelet therapy following drug-eluting stent implantation: A systemic review and meta-analysis of randomized controlled trials with longer follow up.Mechanisms of erosion of atherosclerotic plaques.Clinical and economic outcomes among elderly myocardial infarction survivors in the United States.Economic and social impact of increased cardiac rehabilitation uptake and cardiac telerehabilitation in Belgium - a cost-benefit analysis.Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database.Personality factors and depression as predictors of hospital-based health care utilization following acute myocardial infarction.Frailty is a short-term prognostic marker in acute coronary syndrome of elderly patients.Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.Dual antiplatelet therapy for secondary prevention of coronary artery disease.The role of national registries.
P2860
Q28600880-D2D4A0B0-B235-4560-ACD8-FC0718953F3DQ30953720-EDA35689-C33E-4479-A5A2-5B49E14613ACQ33561481-566EE2AA-0900-43C4-8D38-878F72B6B3EAQ33589630-825625AB-FEA5-48C2-A396-7E6BBFAB4D44Q33898330-FB03F002-AB96-4A33-9A84-887D28B13F99Q36035664-55A2E740-C4A2-44E2-95BD-A6940FC9EEB2Q36195380-06476F7B-92B2-466C-863F-09A0433C0FBEQ36273176-6C770BFD-2A2D-4A2F-AF5F-CDBCC4AB5F65Q36306613-1FD3B518-CEC5-4B98-8B35-A3D3487E1C49Q36369122-3A0FD53E-7695-4299-BF65-BEB1271F5E11Q36602802-822546FD-EC69-4D0D-831F-34D4F60A234DQ36681493-4863E4EB-474D-4B9D-A532-FF2ECDFEFE4EQ36762574-137F68B2-EF44-492E-8409-3A4B2536C774Q36920061-9CACB65D-B3A6-4276-AD32-8CE405D3F7CBQ37399211-2716CD84-501F-48F5-99A3-EEC1264930E2Q37454956-13454CCD-04E8-4EEC-8424-462066D656C8Q37703242-58A958BE-49B2-4C4C-B39E-BAC81C8608D7Q38570608-345FB4A0-C1D8-44BD-8D71-1D7225860F07Q38577755-272E43D0-E2DA-47D3-8E2F-02913DFE4A32Q38612448-D45E61EF-1914-4AD4-AE70-9ED301137AD0Q38685680-4E8ABCE6-1004-4680-AE65-DD6D18AC7373Q38724843-D9312A3C-CA52-439C-B8CD-721530F2A009Q38726573-075681C7-74C4-4F15-970D-FBF18987F776Q38837527-5673C410-3F78-483B-A24F-99EF301A7A7DQ38859458-ABE90A77-665B-4B2B-98F2-12BA05110C8BQ38866836-63F0ECFE-2C13-480A-B1DC-5BEDBEA8502BQ38869502-7CDE101C-0AE5-46FA-85B4-30AD8A8CC832Q38879636-8031CD1A-EB06-4733-9D66-51D15F326FD2Q38974884-83BA462F-AEBD-428A-93CE-13FF2CD44C19Q39154873-A867677A-89D8-4FA1-9DB5-29E08B94AD30Q39338217-5689E552-DC9D-420E-ABF3-261A026C1830Q39418237-2F422956-BDE4-4E78-B2E2-5B8DEB8CB99FQ39451145-2DDB15C0-8DA9-4DAF-9B72-965B3F826672Q40097446-A59749FF-1A3B-4EF6-A94A-9A74A32C55FCQ40272818-636C06F4-6945-4E63-8F28-58308DA20017Q40605415-99B92826-2EAC-48BB-B06B-780CC2CA569CQ40793052-35156913-74F0-44E1-AE51-AB5A9014AE35Q41438653-EEDA1828-7C35-4585-813C-3F6F73BFA3A0Q42650020-226604A9-C3D5-4AF0-A967-57206057EF92Q43587863-D44CBB48-F3FC-4A7F-8D33-6ED8B79ED353
P2860
Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Cardiovascular risk in post-my ...... ce of a long-term perspective.
@ast
Cardiovascular risk in post-my ...... ce of a long-term perspective.
@en
type
label
Cardiovascular risk in post-my ...... ce of a long-term perspective.
@ast
Cardiovascular risk in post-my ...... ce of a long-term perspective.
@en
prefLabel
Cardiovascular risk in post-my ...... ce of a long-term perspective.
@ast
Cardiovascular risk in post-my ...... ce of a long-term perspective.
@en
P2093
P2860
P921
P356
P1476
Cardiovascular risk in post-my ...... ce of a long-term perspective.
@en
P2093
Hans Hjelm
Magnus Janzon
Martin Henriksson
Pål Hasvold
Tomas Jernberg
P2860
P304
P356
10.1093/EURHEARTJ/EHU505
P577
2015-01-13T00:00:00Z